We are international
Donate
trials TEXT SIZE   
drugs & procedures in clinical trials    back

VORINOSTAT

Vorinostat is an oral histone deacetylase inhibitor (HDACi) that alters gene expression and protein activity. It has shown promise in the treatment of multiple myeloma.

Clinical Trial Fact Sheets
Brochures/Posters
Open Clinical Trials
Articles
Webcasts
Links
09.11.09  VANTAGE 088 FACT SHEET: Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma
Merck-sponsored Phase III multi-national study in patients with relapsed or refractory multiple myeloma.

09.11.09  VANTAGE 095 FACT SHEET: Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma
Merck-sponsored Phase IIb multi-national study in patients with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens.